About Hyalex Orthopaedics
Hyalex Orthopaedics is a Boston-based medical device start-up focused on developing and commercializing new products that feature HYALEX™ materials technology. Unlike other polymers, synthetic HYALEX material has the unique capability of maintaining low friction and low wear under the high loads encountered in human joints. HYALEX Orthopaedics' products are in the development stage and have not been approved for use in humans by any regulatory agency.
Founders: David Myung and Lampros Kourtis
CEO: Mira Sahney
7 articles about Hyalex Orthopaedics
BioSpace Movers & Shakers, Jan. 28
1/28/2022Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Hyalex Orthopaedics Appoints Carl Vause, Orthopaedic Industry Veteran, as Chief Executive Officer and President and Names Mike Hawkins, Ph.D., Chief Technical Officer
Hyalex Orthopaedics, a privately-held medical device company developing transformational cartilage biomimetic products, announced the appointment of Carl Vause as its new chief executive officer and president.
Hyalex Orthopaedics receives FDA Breakthrough Device Designation for novel HYALEX® Cartilage System
Hyalex Orthopaedics, Inc., announced that the HYALEX® Cartilage System has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).
Hyalex Orthopaedics, synthetic cartilage company, adds new funding; expanding Series A total to $33MM
Brad Vale, PhD, DVM General Partner at Strategic Healthcare Investment Partners, will join the board as part of the financing
Hyalex Orthopaedics launched in May 2017 as a medical device company that intends to advance new products featuring HYALEX technology, a synthetic polymer that mimics cartilage.
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
Boston's Hyalex Orthopaedics Nabs $16 Million, Names Ex-Smith & Nephew Inc. Exec as New CEO